Browsing by Author Hall, M
Showing results 1 to 20 of 33
next >
Issue Date | Title | Author(s) |
---|---|---|
7-Sep-2021 | Circulating tumour cells and circulating cell-free DNA in lung cancer patients: A comparison between Thoracotomy and Video-Assisted Thoracoscopic Surgery | Katopodis, P; Anikin, V; Kishore, U; Carter, T; Hall, M; Asadi, N; Polychronis, A; Karteris, E |
26-Feb-2021 | COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease | Katopodis, P; Kerslake, R; Davies, J; Randeva, HS; Chatha, K; Hall, M; Spandidos, DA; Anikin, V; Polychronis, A; Robertus, JL; Kyrou, I; Karteris, E |
2020 | Co‑expression of peripheral olfactory receptors with SARS‑CoV‑2 infection mediators: Potential implications beyond loss of smell as a COVID‑19 symptom | Kerslake, R; Hall, M; Randeva, H; Spandidos, D; Chatha, K; Kyrou, I; Karteris, E |
25-Mar-2023 | Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting | Alizzi, Z; Roxburgh, P; Cartwright, D; McLaren, A; Park, S; Jones, R; Greening, S; Hudson, E; Green, C; Gray, S; Khalique, S; Karteris, E; Hall, M |
17-Jul-2019 | Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian Cancer | Kumar, J; Chudasama, D; Charlotee, R; Kubista, M; Sjoback, R; Chatterjee, J; Anikin, V; Karteris, E; Hall, M |
15-Jun-2023 | Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study | Alizzi, Z; Gogbashian, A; Karteris, E; Hall, M |
2016 | Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro | Rogers-Broadway, KR; Chudasama, D; Pados, G; Tsolakidis, D; Goumenou, A; Hall, M; Karteris, E |
31-Oct-2018 | Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry | Rogers‑Broadway, KR; Kumar, J; Sisu, C; Wander, G; Mazey, E; Jeyaneethi, J; Pados, G; Tsolakidis, D; Klonos, E; Grunt, T; Hall, M; Chatterjee, J; Karteris, E |
1-Feb-2022 | Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro | Filipe, A; Chudasama, D; Kerslake, R; Jeyaneethi, J; Anikin, V; Kyrou, I; Randeva, H; Sisu, C; Hall, M; Karteris, E |
8-Oct-2022 | Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer | Kerslake, R; Sisu, C; Panfilov, S; Hall, M; Khan, N; Jeyaneethi, J; Randeva, H; Kyrou, I; Karteris, E |
24-Jul-2017 | Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individuals | Holzinger, ER; Verma, SS; Moore, CB; Hall, M; De, R; Gilbert-Diamond, D; Lanktree, MB; Pankratz, N; Amuzu, A; Burt, A; Dale, C; Dudek, S; Furlong, CE; Gaunt, TR; Kim, DS; Riess, H; Sivapalaratnam, S; Tragante, V; Van Iperen, EPA; Brautbar, A; Carrell, DS; Crosslin, DR; Jarvik, GP; Kuivaniemi, H; Kullo, IJ; Larson, EB; Rasmussen-Torvik, LJ; Tromp, G; Baumert, J; Cruickshanks, KJ; Farrall, M; Hingorani, AD; Hovingh, GK; Kleber, ME; Klein, BE; Klein, R; Koenig, W; Lange, LA; MOrz, W; North, KE; Charlotte Onland-Moret, N; Reiner, AP; Talmud, PJ; Van Der Schouw, YT; Wilson, JG; Kivimaki, M; Kumari, M; Moore, JH; Drenos, F; Asselbergs, FW; Keating, BJ; Ritchie, MD |
2015 | Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE | Greenhalgh, J; Longworth, L; Crossan, C; Singh, J; Bagust, A; Beale, S; Richardson, M; Banks, L; Kotas, E; Hall, M |
27-Apr-2024 | Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model | Morea, A; Saravi, S; Sisu, C; Hall, M; Tosi, S; Karteris, E; Storlazzi, CT |
27-Dec-2022 | Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer | Kerslake, R; Panfilov, S; Mustafa, N; Hall, M; Kyrou, I; Randeva, H; Karteris, E; Godfrey, R |
2023 | Exploring novel strategies for assessing response to treatment in patients with advanced ovarian cancer, in particular the role and potential of non-haemopoetic circulating cells and DECT imaging | Alizzi, Zena |
2-Sep-2020 | H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival | Saravi, S; Katsuta, E; Jeyaneethi, J; Amin, HA; Kaspar, M; Takabe, K; Pados, G; Drenos, F; Hall, M |
10-Aug-2020 | Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients | Carter, TJ; Jeyaneethi, J; Kumar, J; Karteris, E; Glynne-Jones, R; Hall, M |
8-Nov-2017 | Identification of novel cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers | Chudasama, D; Bo, V; Hall, M; Anikin, V; Jeyaneethi, J; Gregory, J; Pados, G; Tucker, A; Harvey, A; Pink, R; Karteris, E |
5-May-2021 | Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer | Zahra, A; Dong, Q; Hall, M; Jeyaneethi, J; Silva, E; Karteris, E; Sisu, C |
4-Aug-2023 | Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: Association with treatment outcomes | Alizzi, Z; Saravi, S; Khalique, S; Mcdonald, T; Karteris, E; Hall, M |